Earnings Per Share (GAAP)
$-0.06
vs $-0.10 est. (narrower loss, 37.2%)
Loss narrows sharply. Trevi Therapeutics, Inc. (NASDAQ: TRVI) reported a loss of $0.06 per share for Q4 2025, narrower than the consensus estimate of $0.10 per share. The biotech posted a narrower loss than expected by 37.2%, marking its fourth consecutive quarter of beating analyst expectations. The company’s net loss totaled $8.3 million for the quarter. Year-over-year, the loss per share improved 45.5% from the $0.11 loss reported in Q4 2024.
No revenue yet. Trevi reported zero revenue for Q4 2025, matching the $0 consensus estimate. The company remains pre-commercial, consistent with its Q4 2024 results when it also reported no revenue. As a clinical-stage biotechnology company, Trevi’s valuation hinges on pipeline progress rather than current sales. The company’s operating loss for the quarter was $10.2 million.
Analyst support remains strong. Wall Street maintains unanimous bullish sentiment on TRVI, with 11 analysts covering the stock—2 rating it Strong Buy and 9 rating it Buy, with zero Hold or Sell ratings. This consensus has held steady for at least three months. The stock closed at $11.16 on volume of 1.02 million shares, well above its 52-week low of $4.85 but below its $14.39 high.
What to Watch: Monitor the company’s earnings call replay for updates on clinical trial timelines and cash runway—critical catalysts for a pre-revenue biotech burning through $10 million per quarter in operating expenses.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
-1024x683.jpg "Strait Outta Hormuz: Getting the Iran Oil Story Straight")
